SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Jackie Robinson Synthetic CCD

PatientJackie Robinson
Date of birth1974-01-31
IdentifiersMRN HR-ML037-SYN; SSN (made up) 000-37-2286
Document date2026-11-01
AuthorMarcus Delacroix-Hale, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Visit for blurred vision and new floaters, chest tightness on stairs, calf pain on walking and numb feet, in a man with long-standing diabetes six weeks after the death of his son. Concerns: He is afraid of losing his sight and his independence; He wants to keep working and to stay strong for his family after his son's death. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route2025-03-03activeS
Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70At bedtime, by the gradual titration planSubcutaneous route2025-03-03activeS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2025-03-03 to 2026-07-29completedS
Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake)One tablet dailyOral route2026-07-27activeS
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2025-03-03activeS
Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutesAs needed for severe low blood sugarNasal route2026-07-27activeS
Metoprolol succinate extended-release 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-08-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the firstAs needed for chest pain, up to three dosesSublingual route2026-08-12activeS
Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route2026-07-29activeS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparationOne tablet daily, with sick-day rulesOral route2026-07-29activeS
Ezetimibe 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-10-26activeS
Dulaglutide 0.75 mg/0.5 mL pen, one injection under the skin once a week; dose to rise to 1.5 mg after at least four weeks only if the retina remains stableOnce a week, same day each weekSubcutaneous route2026-10-26activeS

Procedures

ProcedureDatesStatusEvidence
Twelve-lead electrocardiogram2026-07-27 to 2026-07-27completedS
Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses2026-07-27 to 2026-07-27completedS
Dilated fundus examination of both eyes with B-scan ultrasound of the right eye, at the retina clinic2026-07-29 to 2026-07-29completedS
Optical coherence tomography of the macula, both eyes2026-07-29 to 2026-07-29completedS
Intravitreal injection of aflibercept 2 mg, both eyes (injection 1)2026-07-29 to 2026-07-29completedS
Regadenoson myocardial perfusion stress study, at the cardiology clinic2026-08-12 to 2026-08-12completedS
Wound care of the right heel blister by the clinic nurse: cleansing, non-adherent dressing and a heel offloading shoe2026-08-17 to 2026-08-17completedS
Intravitreal injection of aflibercept 2 mg, both eyes (injection 2), at the retina clinic2026-08-26 to 2026-08-26completedS
Advance care planning conversation, about 20 minutes2026-09-21 to 2026-09-21completedS
Optical coherence tomography of the macula, both eyes, at the retina clinic2026-09-23 to 2026-09-23completedS
Intravitreal injection of aflibercept 2 mg, both eyes (injection 3), at the retina clinic2026-09-23 to 2026-09-23completedS
Panretinal photocoagulation, right eye (first session), at the retina clinic2026-10-07 to 2026-10-07completedS

Immunizations

DateVaccineStatusEvidence
2026-09-21Influenza vaccine, inactivated, this seasoncompletedS
2026-09-21Pneumococcal conjugate vaccine PCV20completedS
2026-09-21Recombinant zoster vaccine, dose 1 of 2completedS
2026-10-26COVID-19 vaccine, mRNA, this seasoncompletedS
2026-10-26Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
about 1957Diabetes diagnosed at about 37, around his retirement from baseballD (CLM-0005)
by 1969Nerve and artery damage in both legsD (CLM-0006)
1970Two mild strokesD (CLM-0007)

Family History

RelativeConditionAge at deathEvidence
brotherTwo of his brothers had diabetesD (CLM-0005)
natural sonHis eldest son died in an automobile accident at 2424D (CLM-0011)

Health Concerns

ConcernStatusEvidence
He is afraid of losing his sight and his independenceactiveS
He wants to keep working and to stay strong for his family after his son's deathactiveS

Assessment

Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 9.2 on 2026-10-26; Glucose [Mass/volume] in Serum or Plasma 248 on 2026-07-27; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-10-26; Potassium [Moles/volume] in Serum or Plasma 4.7 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 1.18 on 2026-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 74 on 2026-10-26; Albumin/Creatinine [Mass Ratio] in Urine 54 on 2026-10-26; Cholesterol [Mass/volume] in Serum or Plasma 150 on 2026-10-26; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 74 on 2026-10-26; Cholesterol in HDL [Mass/volume] in Serum or Plasma 40 on 2026-10-26; Triglyceride [Mass/volume] in Serum or Plasma 180 on 2026-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 on 2026-10-26; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-07-27; Hemoglobin [Mass/volume] in Blood 13.9 on 2026-07-27; Platelets [#/volume] in Blood by Automated count 250 on 2026-07-27; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 380 on 2026-07-27; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-07-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-10-26; Visual acuity best corrected Right eye by ETDRS eye chart 35 on 2026-07-29; Visual acuity best corrected Left eye by ETDRS eye chart 56 on 2026-07-29; Macular grid.center subfield thickness by OCT 468 on 2026-07-29; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 2 on 2026-09-21; Total score [AUDIT-C] 0 on 2026-09-21; Ankle-brachial index 0.74 on 2026-08-26 [S]

Strengths and supports: Strengths: discipline, a long habit of facing pressure in public, his faith, his work for civil rights, and a household that supports him [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arrangedresolvedconfirmed H53.8S — Synthetic presenting finding, superseded by the retinal diagnosis two days later.
Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arrangedresolvedconfirmed R07.89S — Synthetic presenting finding, superseded by the coronary diagnosis after the stress test.
Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%)activeconfirmed E11.65S — Synthetic modern episode linked to his documented diabetes.
Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters leftactiveconfirmed E11.3513S — Synthetic retinal findings anchored to his documented loss of vision.
Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasoundactiveconfirmed H43.11S — Synthetic finding.
Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg)activeconfirmed I12.9S — Synthetic modern episode linked to his documented high blood pressure.
Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79activeconfirmed E11.22S — Synthetic kidney findings.
Chronic kidney disease G2 A2activeconfirmed N18.2S — Synthetic kidney finding.
Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulsesactiveconfirmed E11.51S — Synthetic modern episode linked to the documented artery damage in his legs.
Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testingactiveconfirmed E11.42S — Synthetic modern episode linked to the documented nerve damage in his legs.
History of two mild strokes a year ago, without lasting weaknessactiveconfirmed Z86.73S — Synthetic modern coding of the documented strokes.
Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dLactiveconfirmed E78.5S — Synthetic laboratory finding.
Bereavement: his eldest son died in a car crash six weeks agoactiveconfirmed Z63.4S — Synthetic modern coding of a documented loss; grief is treated as grief, not as a disorder.
Coronary artery disease with stable angina on climbing stairs: a small reversible inferior perfusion defect on regadenoson stress imaging, ejection fraction 56%; medical therapy chosen with cardiologyactiveconfirmed I25.119S — Synthetic coronary diagnosis anchored to his documented heart disease; no heart attack is recorded before the episode.
Friction blister of the right heel from new shoes, unroofed, 2.5 by 2 cm, clean base, without infection, in a neuropathic foot with peripheral artery diseaseresolvedconfirmed S90.821AS — Synthetic intercurrent problem at an unscheduled visit; it does not echo a documented event.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-27Hemoglobin A1c/Hemoglobin.total in Blood10.4%Below 5.7% is normal; his first goal below 8%, then below 7%, lowered graduallyHighS
2026-07-27Glucose [Mass/volume] in Serum or Plasma248mg/dL70-139 mg/dLHighS
2026-07-27Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-07-27Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-07-27Creatinine [Mass/volume] in Serum or Plasma1.12mg/dL0.74-1.35 mg/dLNormalS
2026-07-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M79mL/min/{1.73_m2}90 or higher is normal; 60 to 89 is mildly decreased (G2)LowS
2026-07-27Albumin/Creatinine [Mass Ratio] in Urine86mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2)HighS
2026-07-27Cholesterol [Mass/volume] in Serum or Plasma226mg/dL<=199 mg/dLHighS
2026-07-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation142mg/dLGoal below 55 mg/dL with atherosclerotic diseaseHighS
2026-07-27Cholesterol in HDL [Mass/volume] in Serum or Plasma38mg/dL>=40 mg/dLLowS
2026-07-27Triglyceride [Mass/volume] in Serum or Plasma230mg/dL<=149 mg/dLHighS
2026-07-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
2026-07-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-48 U/LNormalS
2026-07-27Hemoglobin [Mass/volume] in Blood13.9g/dL13.5-17.5 g/dLNormalS
2026-07-27Platelets [#/volume] in Blood by Automated count25010*3/uL150-400 10*3/uLNormalS
2026-07-27Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma380pg/mL232-1245 pg/mLNormalS
2026-07-27Thyrotropin [Units/volume] in Serum or Plasma1.8m[IU]/L0.4-4.5 mIU/LNormalS
2026-07-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S
2026-07-29Visual acuity best corrected Right eye by ETDRS eye chart35{letters}85 letters is about 20/20; 35 letters is about 20/200LowS
2026-07-29Visual acuity best corrected Left eye by ETDRS eye chart56{letters}85 letters is about 20/20; 55 letters is about 20/80LowS
2026-07-29Macular grid.center subfield thickness by OCT412um200-300 umHighS
2026-07-29Macular grid.center subfield thickness by OCT468um200-300 umHighS
2026-09-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]2{score}S
2026-09-21Total score [AUDIT-C]0{score}S
2026-08-26Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-08-26Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-08-26Creatinine [Mass/volume] in Serum or Plasma1.22mg/dL0.74-1.35 mg/dLNormalS
2026-08-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M71mL/min/{1.73_m2}90 or higher is normal; 60 to 89 is mildly decreased (G2)LowS
2026-08-26Ankle-brachial index0.68{ratio}1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormalLowS
2026-08-26Ankle-brachial index0.74{ratio}1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormalLowS
2026-10-26Hemoglobin A1c/Hemoglobin.total in Blood9.2%Below 5.7% is normal; his first goal below 8%, then below 7%, lowered graduallyHighS
2026-10-26Albumin/Creatinine [Mass Ratio] in Urine54mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2)HighS
2026-10-26Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-26Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma1.18mg/dL0.74-1.35 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M74mL/min/{1.73_m2}90 or higher is normal; 60 to 89 is mildly decreased (G2)LowS
2026-10-26Cholesterol [Mass/volume] in Serum or Plasma150mg/dL<=199 mg/dLNormalS
2026-10-26Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation74mg/dLGoal below 55 mg/dL with atherosclerotic diseaseNormalS
2026-10-26Cholesterol in HDL [Mass/volume] in Serum or Plasma40mg/dL>=40 mg/dLNormalS
2026-10-26Triglyceride [Mass/volume] in Serum or Plasma180mg/dL<=149 mg/dLHighS
2026-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-55 U/LNormalS
2026-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-07-27Body height180cmS
2026-07-27Body weight104kgS
2026-07-27Body mass index (BMI) [Ratio]32.1kg/m2S
2026-07-27Systolic blood pressure152mm[Hg]S
2026-07-27Diastolic blood pressure92mm[Hg]S
2026-07-27Heart rate84/minS
2026-07-27Respiratory rate16/minS
2026-07-27Body temperature36.7CelS
2026-07-27Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-07-29Body height180cmS
2026-07-29Body weight103.8kgS
2026-07-29Body mass index (BMI) [Ratio]32kg/m2S
2026-07-29Systolic blood pressure148mm[Hg]S
2026-07-29Diastolic blood pressure90mm[Hg]S
2026-07-29Heart rate82/minS
2026-07-29Respiratory rate16/minS
2026-07-29Body temperature36.6CelS
2026-07-29Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-08-17Body height180cmS
2026-08-17Body weight103.2kgS
2026-08-17Body mass index (BMI) [Ratio]31.9kg/m2S
2026-08-17Systolic blood pressure136mm[Hg]S
2026-08-17Diastolic blood pressure84mm[Hg]S
2026-08-17Heart rate64/minS
2026-08-17Respiratory rate16/minS
2026-08-17Body temperature36.7CelS
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-08-26Body height180cmS
2026-08-26Body weight102.8kgS
2026-08-26Body mass index (BMI) [Ratio]31.7kg/m2S
2026-08-26Systolic blood pressure134mm[Hg]S
2026-08-26Diastolic blood pressure80mm[Hg]S
2026-08-26Heart rate60/minS
2026-08-26Respiratory rate16/minS
2026-08-26Body temperature36.6CelS
2026-08-26Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-21Body height180cmS
2026-09-21Body weight102.2kgS
2026-09-21Body mass index (BMI) [Ratio]31.5kg/m2S
2026-09-21Systolic blood pressure128mm[Hg]S
2026-09-21Diastolic blood pressure78mm[Hg]S
2026-09-21Heart rate62/minS
2026-09-21Respiratory rate16/minS
2026-09-21Body temperature36.6CelS
2026-09-21Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-26Body height180cmS
2026-10-26Body weight101.4kgS
2026-10-26Body mass index (BMI) [Ratio]31.3kg/m2S
2026-10-26Systolic blood pressure126mm[Hg]S
2026-10-26Diastolic blood pressure76mm[Hg]S
2026-10-26Heart rate60/minS
2026-10-26Respiratory rate16/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-07-27Visit for blurred vision and new floaters, chest tightness on stairs, calf pain on walking and numb feet, in a man with long-standing diabetes six weeks after the death of his sonfinishedS
2026-07-29Review after the retina consultation and first eye injections: retinal diagnosis, glucose, blood pressure and kidney medicinesfinishedS
2026-08-17Same-day sick visit for a blister on the right heelfinishedS
2026-08-26Four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injectionsfinishedS
2026-09-21Periodic adult preventive visitfinishedS
2026-10-26Three-month review: A1c, urine albumin, lipids, eyes after laser treatment, heart, legs, grief, and a GLP-1 receptor agonistfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Urgent retina consultation within 48 hours for blurred vision with new floaters in a man with long-standing diabetes: dilated examination, OCT, and treatment of any proliferative retinopathy or macular edema; same-day attendance for a curtain over the vision or flashescompletedGL-AAO-DR-2025, GL-ADA-RETFOOT-2026S
Glucose: continue metformin and basal insulin, titrated slowly by a written plan so that the A1c falls gradually; rescue glucagon; diabetes self-management education adapted for low vision (a talking glucose meter, an insulin pen with audible dose clicks, large-print plans)completedGL-ADA-GLY-2026, GL-ADA-PHARM-2026, GL-CMID-2026S
Cardiovascular risk: atorvastatin increased to 80 mg, aspirin continued, baseline ECG; cardiology evaluation of exertional chest tightness with a pharmacologic stress test, since calf pain limits walkingcompletedGL-ADA-CVD-2026, GL-AHA-CCD-2023, GL-AHA-STROKE-2021, GL-CMID-2026S
Legs and feet: comprehensive foot examination today; ankle-brachial index; daily foot checks with a magnifying mirror and a bright lamp, protective shoes; podiatrycompletedGL-ADA-RETFOOT-2026, GL-ACC-PAD-2024S
Kidneys: repeat urine albumin and kidney function after any change in kidney medicines; no NSAIDscompletedGL-ADA-CKD-2026, GL-KDIGO-CKD-2024S
Grief and mood: acknowledge the loss, PHQ-9 now and at three months, and an offer of the health center's grief counselor, which he accepted; call or text 988 if thoughts of self-harm ever arisecompletedGL-USPSTF-DEP-2023, GL-ADA-BEH-2026, GL-CMID-2026S
Coronary disease, with cardiology: metoprolol succinate 25 mg daily and nitroglycerin as needed; continue high-intensity statin and aspirin; no revascularization now for a small area of ischemia with stable symptoms; review with cardiology in three months or sooner for worse or more frequent chest paincompletedGL-AHA-CCD-2023, GL-ADA-CVD-2026, GL-CMID-2026S
Heel blister: daily dressing by the visiting nurse three times a week and by him on other days with a large-print guide; heel offloading shoe; podiatry within two days; review weekly; a vascular surgery opinion if it is not healing within four weeks or the ankle-brachial index is very lowcompletedGL-IWGDF-2023, GL-ACC-PAD-2024, GL-ADA-RETFOOT-2026S
On the retina specialist's advice: aflibercept injections in both eyes monthly for three doses, then treat-and-extend; panretinal photocoagulation to the right eye once the hemorrhage clears, and to the left if new vessels persist; vitrectomy if the hemorrhage does not clear within one to three months; low-vision evaluation; aspirin continued; glucose lowered gradually, and a GLP-1 receptor agonist only after the retina is stable, with retina review monthlycompletedGL-AAO-DR-2025, GL-ADA-RETFOOT-2026, GL-SUSTAIN6-2016S
Lisinopril increased to 40 mg and empagliflozin 10 mg started, with written sick-day rules; potassium and creatinine in four weeks; urine albumin at three monthscompletedGL-ADA-CKD-2026, GL-ADA-CVD-2026, GL-KDIGO-CKD-2024, GL-CMID-2026S
Peripheral artery disease: supervised exercise therapy three times a week for twelve weeks once the heel has healed; podiatry every two to three months; vascular review if walking does not improve or any wound fails to healcompletedGL-ACC-PAD-2024, GL-IWGDF-2023, GL-CMID-2026S
Dulaglutide 0.75 mg weekly started with the retina specialist's agreement, rising only if the retina stays stable at monthly review; ezetimibe 10 mg added; lipids four to eight weeks after the change, booked before he leaves the cliniccompletedGL-ADA-PHARM-2026, GL-ADA-CVD-2026, GL-SUSTAIN6-2016, GL-AAO-DR-2025, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Vision kept or improved: proliferative disease regressed and macular edema reduced on anti-VEGF injections and laser2026-10-26activeHemorrhage clearing, new vessels regressing after three injections and laser to the right eye; macular thickness down in both eyes; acuity improvedS
A1c falling by about one point every three months without low blood sugar, to below 8% within six months and then below 7%2026-10-26active10.4% to 9.2% at three months; no low blood sugarS
Blood pressure below 130/80 mmHg2026-10-26completed126/76 in the clinicS
LDL cholesterol below 55 mg/dL2026-10-26active142 to 74 mg/dL on atorvastatin 80 mg; ezetimibe addedS
Walk at least three blocks without stopping, through supervised exercise2026-10-26activeFrom one block to two and a half blocksS
Feet kept intact: daily foot checks he can do with low vision, protective footwear, and prompt care for any skin break2026-10-26activeA heel blister found early, healed in five weeks; footwear providedS
Grief acknowledged and supported, with depression screening repeated2026-10-26activeMeeting the health center's grief counselor; PHQ-9 9 to 6S

Functional Status

Mental Status